The FOURIER Trial. On behalf of the FOURIER Investigators. American Heart Association Scientific Sessions November 13, 2017
|
|
- Prosper Paul Garrison
- 6 years ago
- Views:
Transcription
1 The FOURIER Trial Sabina A. Murphy, Terje R. Pedersen, Zbigniew A. Gaciong, Richard Ceska, Marat V. Ezhov, Derek Connolly, Oleg Kraydashenko, J. Wouter Jukema, Kalman Toth, Matti J. Tikkanen, Kyungah Im, Stephen D. Wiviott, Christopher Kurtz, Narimon Honarpour, Robert P. Giugliano, Anthony C. Keech, Peter S. Sever, Marc S. Sabatine On behalf of the FOURIER Investigators American Heart Association Scientific Sessions November 13, 2017
2 PCSK9 blocks LDLR-Recycling More LDL-Receptor Less LDL-C AB More Less LDL-Receptor Higher Less LDL-C modifiziert nach Cohen JC, Hobbs HH. Science 2013 (6133):689-90
3 Statin vs. Statin + PCSK9 antibody
4 Statin vs. Statin + PCSK9 antibody Sabatine et al N Engl J Med. 2017;376:
5 Hypothesis PCSK9 inhibition with evolocumab reduces total vascular events, both first and recurrent!
6 Type of Primary Endpoint Events Total PEP = 4906 First Events Additional Events CV Death MI Stroke Hosp for UA Coronary Revasc
7 # Events Total Primary Endpoint Events st Event HR 0.85 ( )
8 # Events Total Primary Endpoint Events Additional Events RR 0.74 ( ) st Event HR 0.85 ( )
9 # Events Total Primary Endpoint Events Total Events RR 0.82 (95%CI ) P< Additional Events RR 0.74 ( ) st Event HR 0.85 ( )
10 Primary Endpoint Events: Wei, Lin, Weissfeld Model HR (95% CI) 1 Event (n=2907) 2 Events (n=1333) 3 Events (n=373) 4+ Events (n=152) HR Better HR 0.76 HR 0.74 HR 0.85 Better
11 Events per 1,000 Patients Total Primary Endpoint Events Number of Events Prevented for 1,000 Patients Treated with for 3 Years First Event Only
12 Events per 1,000 Patients Total Primary Endpoint Events Number of Events Prevented for 1,000 Patients Treated with for 3 Years First Event Only -52 Total Events
13 CV Death, MI or Stroke CV Death, MI or Stroke FOURIER subanalysis PAD CV Death, MI or stroke in patients with and without PAD CV Death, MI or stroke in patients with PAD and no MI or stroke 14% 12% 10% PAD N=3,642 27% RRR HR 0.73 (0.59; 0.91) P= ,0% PAD 3,5% ARR NNT 2.5y 29 14% 12% 10% PAD (no MI/stroke, N=1505) 43% RRR HR 0.57 (0.38; 0.88) P= ,3% 8% 6% 4% 2% 0% No PAD N=23,922 HR %CI (0.73; 0.90) P<0.001 P-interaction = Days from randomization 9,5% 7,6% 6,2% No PAD 1,4% ARR NNT 2.5y 72 8% 6% 4% 2% 0% Days from randomization 5,5% PAD 4,8% ARR NNT 2.5y 21 Outcome HR 95%CI MACE 0.57 (0.38; 0.88) CV death 0.78 (0.39; 1.57) MI 0.66 (0.38; 1.14) Stroke 0.30 (0.11; 0.82) Bonaca M LBS-02 Bonaca M et al, Circulation 2017;137. DOI: /CIRCULATIONAHA Congress Update Cardiovascular AHA 2017
14 Major, adverse limb events FOURIER subanalysis PAD Major adverse limb events 0,5% 0,4% All patients N=27,564 42% RRR HR 0.58 (0.38; 0.88) P= ,45% 0,3% 0,2% 0,27% 0,1% 0,0% Days from randomization Outcome HR 95%CI MALE 0.58 (0.38; 0.88) ALI or major amputation ; 0.89 ALI ; 0.97 Major amputation ; 1.95 Urgent revascularization ; 1.26 Bonaca M LBS-02 Bonaca M et al, Circulation 2017;137. DOI: /CIRCULATIONAHA Congress Update Cardiovascular AHA 2017
15 CV death, MI, or stroke FOURIER subanalysis history of MI results Benefit of EvoMab based on time from qualifying MI Benefit of EvoMab based on multivessel disease Qualifying MI <2 years ago Qualifying MI 2 years ago Multivessel disease No multivessel disease 12% 10% 8% 6% 24% RRR HR 0.76 (95%CI 0.64; 0.89) P< ,8% 2.9% NNT 35 7,9% 12% 10% 8% 6% 13% RRR HR 0.87 (95%CI 0.76; 0.99) P< % 8.3% 14% 12% 10% 8% 6% 30% RRR HR 0.70 (95%CI 0.58; 0.84) P< % 3.4% NNT % 14% 12% 10% 8% 6% 11% RRR HR 0.89 (95%CI 0.79; 1.00) P< % 4% 2% 4% 2% 1.0% NNT 101 4% 2% 4% 2% 7.6% 0% 0% 0% 0% 1.3% NNT 78 P interaction =0.18 P interaction = Months after randomization Months after randomization Sabatine MS LBS-02 Congress Update Cardiovascular AHA 2017
16 Summary Addition of the PCSK9 inhibitor evolocumab to statin therapy improved clinical outcomes with reductions in total primary endpoint events Driven by reductions in MI, stroke, and coronary revascularization Taking into account total events more than doubled the number of events prevented with evolocumab compared with first events only Patients with PAD experienced the greatest benefit from evolocumab treatment
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Anthony C. Keech, Armando
More informationCharacterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER
Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER Stephen D Wiviott, Robert P Giugliano, David A Morrow, Gaetano M De Ferrari, Basil S Lewis, Kurt Huber, Julia
More informationLipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Michelle L. O Donoghue, Robert P. Giugliano, Anthony C. Keech, Estella Kanevsky, KyungAh Im, Peter S. Sever, Terje
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationFOURIER Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk
FOURIER Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SM Wasserman, PS Sever, and TR Pedersen, for the
More informationFOURIER. Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk
FOURIER Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk Luis Afonso MD. FACC Professor, Internal Medicine, Division of Cardiology Director Cardiovascular Fellowship
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationEBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial
EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial RP Giugliano, F Mach, K Zavitz, AC Keech, TR Pedersen, MS Sabatine, P Sever, C Kurtz, N Honarpour, BR Ott, on behalf of the EBBINGHAUS
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationDapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Marc P. Bonaca MD MPH for the DECLARE TIMI 58 Investigators American College of Cardiology March 2019
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationWorkshop. Todd Anderson MD / Jacques Genest MD
Workshop Todd Anderson MD / Jacques Genest MD Game-Changing Trials 2017 FOURIER Evolocumab n=27,564 HR 0.80 CANTOS Canakinumab n=10,061 HR 0.85 COMPASS Rivaroxaban + ASA n=27,395 HR 0.76 Key Secondary
More informationPCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH
PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH Presented by: Michael J. Blaha November 16, 2017 1 Financial Disclosures Grants: Amgen Foundation, Aetna Foundation Advisory Boards: Amgen,
More informationAntithrombotic Therapy for Long-Term Secondary Prevention Considerations for Long-Term DAPT
Antithrombotic Therapy for Long-Term Secondary Prevention Considerations for Long-Term DAPT Marc P. Bonaca, MD, MPH Vascular Section, Cardiovascular Division Investigator TIMI Study Group Brigham and Women
More informationIndicações para um inibidor de PCSK9
Indicações para um inibidor de PCSK9 Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical Research Institute Duke University Medical Center 1987 2017: 30 years since first
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationEVIDENCE TO DATE EVOLOCUMAB (REPATHA)
and Clinical Outcomes in Patients with Cardiovascular Disease, March 2017 1 CLINICAL QUESTION In patients with atherosclerotic cardiovascular disease and LDL >1.8mmol/L or non-hdl > 2.6mmol/L, how does
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More informationUpdate on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP
Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular
More informationTHIERS CHAGAS BAHIA FOURIER- ESTUDO DE INIBIÇÃO DA PCSK9 EM PACIENTES DE ALTO RISCO CARDIOVASCULAR
FOURIER- ESTUDO DE INIBIÇÃO DA PCSK9 EM PACIENTES DE ALTO RISCO CARDIOVASCULAR THIERS CHAGAS BAHIA Global Core Content: Do not copy or distribute. Placeholder for Regional/Local Disclaimer. CONFLITO DE
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationZürcher Herzkurs, New drugs and interactions. LDL - what else?
Zürcher Herzkurs, 29.09.2017 New drugs and interactions LDL - what else? Heinz Drexel, MD, FESC, FAHA, FRCP (Ed.) VIVIT Institut am Akademischen Lehrkrankenhaus Feldkirch, A Private Universität im Fürstentum
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationEvidence-based Appraisal of the FOURIER Trial
evidence-based practice Evidence-based Appraisal of the FOURIER Trial Citation: Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl
More informationMartin/Hopkins Estimation, Friedewald and Beta- Quantification of LDL-C in Patients in FOURIER
TAP TO GO BACK TO KIOSK MENU Seth S. Martin, M.D., M.H.S., Robert P. Giugliano, M.D., S.M., 2 Sabina A. Murphy, M.P.H., 2 Scott M. Wasserman, M.D., 3 Peter S. Background Evolocumab, a fully human monoclonal
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationLandmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549
2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes
More information6/30/2018. Cholesterol Management in the 21 st Century: Who Do We Treat? How Low Do We Go? DISCLOSURES
holesterol Management in the 21 st entury: Who Do We Treat? How Low Do We Go? Theodore Feldman MD FA FAP Head of ardiology, FIU Wertheim School of Medicine Medical Director, Prevention and ommunity Health
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationCholesterol, guidelines, targets and new medications
Cholesterol, guidelines, targets and new medications Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers Grants/Research
More informationPrevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Marc S. Sabatine, MD, MPH on behalf of the PEGASUS-TIMI 54 Executive
More informationCanakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationPCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019
PCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019 Professor Gilles Lambert, PhD LaboratoireInserm U1188 Universitéde la Réunion Faculté de Médecine Saint Denis de la Réunion,
More informationRazionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta
Razionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta Giuseppe Musumeci SC Cardiologia Ospedale Santa Croce e Carle Cuneo
More informationBest Medical Therapy for asymptomatic carotid disease
Best Medical Therapy for asymptomatic carotid disease Richard Bulbulia Consultant Vascular Surgeon and Co-PI ACST-2 MRC Population Health Research Unit CTSU, Nuffield Department of Population Health University
More informationHyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine
Hyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine The new england journal of medicine Original Article Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationReducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
New York City Cardiovascular Symposium December 10, 2017 Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Paul M Ridker, MD, MPH
More informationCardiovascular safety & efficacy of lorcaserin in overweight and obese patients Primary results from the CAMELLIA- TIMI 61 Trial
Cardiovascular safety & efficacy of lorcaserin in overweight and obese patients Primary results from the CAMELLIA- TIMI 61 Trial E.A. Bohula, B.M. Scirica, S.E. Inzucchi, A. Keech, D.K. McGuire, S.R. Smith,
More informationCardiovascular safety & efficacy of lorcaserin in overweight and obese patients Primary results from the CAMELLIATIMI 61 Trial
Cardiovascular safety & efficacy of lorcaserin in overweight and obese patients Primary results from the CAMELLIATIMI 61 Trial E.A. Bohula, B.M. Scirica, S.E. Inzucchi, A. Keech, D.K. McGuire, S.R. Smith,
More information2/26/19. Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care. Disclosures. Faculty
Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care Faculty v Karol E. Watson, MD, PhD Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationProblem patients in primary care Patient 4: Peripheral artery disease
Problem patients in primary care Patient 4: Peripheral artery disease Dr Terry McCormack Hambleton Richmond Whitby Clinical Commissioning Group Research Lead 01/05/2014 Delivering clinical research to
More informationCulprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
More informationCholesterol; what are the future lipid targets?
Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationEducational Objectives. Disease Trajectories and CVD Risk Reduction. Hypercholesterolemia Support for LDL-C Causality
Educational Objectives At the conclusion of this activity, participants should be able to: Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationPCSK9 Inhibitors and Canadian Cardiovascular Lipid Guidelines
PCSK9 Inhibitors and Canadian Cardiovascular Lipid Guidelines Robert C. Welsh, MD, FRCPC Professor of Medicine, University of Alberta Zone Clinical Department Head, Cardiac Sciences Inspiring Innovation
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationMedical Therapy for Peripheral Artery Disease
Medical Therapy for Peripheral Artery Disease Beau M. Hawkins, MD, FSCAI University of Oklahoma Health Sciences Center, Oklahoma City, OK Sahil A. Parikh, MD, FSCAI Columbia University Medical Center,
More informationIs the combination of antithrombotics and lowdose anticoagulants worthwhile in PAD The VOYAGER trial
Is the combination of antithrombotics and lowdose anticoagulants worthwhile in PAD The VOYAGER trial Thomas HW Stadlbauer Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationReducing LDL-C with Non- Statin Therapies
Reducing LDL-C with Non- Statin Therapies Michael Miller, MD, FACC, FAHA, FNLA University of Maryland School of Medicine Baltimore, Maryland www.drmichaelmiller.org Disclosures SPIRE (Pfizer): U.S. National
More informationThrombin Receptor Antagonist in Secondary Prevention of Atherothrombosis
Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombosis NCT00526474; Trial funded by Merck David A. Morrow, MD, MPH On behalf of the TRA 2 P-TIMI 50 Steering Committee and Investigators
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationNEWS BRIEFING Diabetes and Cardiovascular Disease. Moderated by: Robert Eckel, MD University of Colorado
NEWS BRIEFING Diabetes and Cardiovascular Disease Moderated by: Robert Eckel, MD University of Colorado 1 EMBARGO POLICY All recordings are for personal use only and not for rebroadcast online or in any
More informationLipids: Guidelines & Best Treatment Options
Lipids: Guidelines & Best Treatment Options Michael Miller, MD, FACC, FAHA, FNLA Professor of Cardiovascular Medicine University of Maryland School of Medicine www.drmichaelmiller.org Michael Miller, MD,
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More informationRe- Setting our COMPASS for Secondary Prevention in Atherosclerotic Vascular Disease
Re- Setting our COMPASS for Secondary Prevention in Atherosclerotic Vascular Disease Robert C. Welsh, MD, FRCPC Professor of Medicine, University of Alberta Zone Clinical Department Head, Cardiac Sciences
More informationTHE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It? THE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It?
James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA Lipidology and Cardiovascular Disease Prevention Clinical Assistant Professor of Medicine NYU Medical School and NYU Center for CV Prevention
More informationThe ACCELERATE Trial
The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,
More informationSupplementary Online Content
Supplementary Online Content Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular
More informationLeading a New Paradigm in Cardiovascular Health Management
Leading a New Paradigm in Cardiovascular Health Management Investor Presentation Cowen and Company 39th Annual Health Care Conference NASDAQ: AMRN Forward-Looking Statements and Disclaimer Forward-looking
More informationTOP CLINICAL TRIALS of 2018 to Impact Your Practice - ASCEND (& REDUCE IT)
TOP CLINICAL TRIALS of 2018 to Impact Your Practice - ASCEND (& REDUCE IT) David de Padua Brasil, MD, MSc, FACC Lavras Federal University/UFLA School of Medicine/Department of Health - Lavras, MG, Brazil
More informationPCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy
PCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy Sergio Fazio, MD, PhD William and Sonja Connor Professor of Preventive Cardiology Professor of Medicine, Physiology & Pharmacology Director, Center for
More informationLa terapia antiaggregante nel paziente con stroke
La terapia antiaggregante nel paziente con stroke Paolo Gresele Dipartimento di Medicina, Sez. Medicina Interna e Cardiovascolare Università di Perugia XXVII Congresso Nazionale FCSA Milano, 20-22 Ottobre
More informationDual Antiplatelet duration in ACS: too long or too short?
Dual Antiplatelet duration in ACS: too long or too short? Leonardo Bolognese, MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Paradigm Shift the ideal duration of DAPT: a moving target Early (stent-related)
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationA New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies
A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention
More informationManaging Lipids and Cardiovascular Risk: Using the Data to Optimize Care
Clinical Updates for Nurse Practitioners and Physician Assistants: 2018 Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care Faculty Robert L. Gillespie, MD, FACC, FASE, FASNC Immediate
More informationLipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More information2017 Update in Internal Medicine: Clinical Dyslipidemia Update
2017 Update in Internal Medicine: Clinical Dyslipidemia Update Erin E. Kershaw, M.D. Chief, Division of Endocrinology Associate Professor of Medicine Certified in Endocrinology, Diabetes, and Metabolism
More informationSupplementary Online Content
Supplementary Online Content Arrieto A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationClopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More informationNew Approaches to Lower LDL-C
New Approaches to Lower LDL-C CSIM 27 October 2016 Jacques Genest MD Cardiovascular Health Across the Lifespan Program McGill University Health Center Disclosure J. Genest MD 2016 Advisory Board, Speaker
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More information